Sanofi's Profit Meets Estimates; Plans €5 Billion Buyback

Sanofi, a leading global biopharmaceutical company, has reported its fourth-quarter financial results, meeting analysts' estimates for profit. The company also announced plans to initiate a €5 billion share buyback program, demonstrating its commitment to returning capital to shareholders. This article explores Sanofi's recent performance, the strategic implications of the buyback program, and the company's ongoing collaboration with Regeneron.